Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §5

REDEFINE-4 — citing documents

Every Institute document that draws on this record.

Document identifier
CEI-TR-0051/5
Series
Trial abstract
Version
3.1
Published
14 Feb 2026
Last reviewed
14 May 2026
Next review
14 May 2028
Identifier
10.71829/cei.trial.51
Certainty
Not rated
Cycle
2026 Q1
Phase
Phase 3
Status
Ongoing

§5Citing documents

This page records every Institute document that draws on REDEFINE-4. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.

§5.1Monograph evidence extracts

Table 7. Monograph evidence extracts that draw on this trial.

§5.2Evidence syntheses

Table 8. Evidence syntheses that include this trial among their contributing studies.

§5.3Other records in the same programme

Table 9. Other records in the REDEFINE — cagrilintide with semaglutide.

RecordTypePhaseStatus
REDEFINE-1Published trial3Reported
REDEFINE-2Published trial3Reported
REDEFINE-1-ADHERENCEProgramme record3Reported
REDEFINE-2-OLEProgramme record3Reported
REDEFINE-4-RENAL-IMPProgramme record1Ongoing
REDEFINE-2-ELDERLYProgramme record3Reported
REDEFINE-4-PKProgramme record1Ongoing
REDEFINE-1-ELDERLYProgramme record3Reported
REDEFINE-2-BIOMARKERProgramme record3Reported
REDEFINE-4-DDIProgramme record1Ongoing
REDEFINE-2-ADHERENCEProgramme record3Reported

§5.4Reference

The Institute holds no publication reference for this trial. Where a trial is real and its report has not been obtained, the record says so rather than citing a source it does not hold.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.